Meta-analysis: the Effect of Lactobacillus Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Treatment.
10.7704/kjhugr.2012.12.2.88
- Author:
Ju Young CHOI
1
;
Ki Nam SHIM
;
Kyoung Ae KONG
;
Kyoung Joo KWON
;
Eun Mi SONG
;
Seong Eun KIM
;
Hye Kyung JUNG
;
Sung Ae JUNG
Author Information
1. Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea. shimkn@ewha.ac.kr
- Publication Type:Meta-Analysis ; Original Article
- Keywords:
Helicobacter pylori;
Lactobacillus;
Eradication;
Side effects
- MeSH:
Amoxicillin;
Clarithromycin;
Diarrhea;
Gastritis;
Helicobacter;
Helicobacter pylori;
Lactobacillus;
Odds Ratio;
Peptic Ulcer;
Proton Pumps
- From:The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2012;12(2):88-95
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Helicobacter pylori (H. pylori) is causally associated with gastritis and peptic ulcer diseases. Recent data have demonstrated that triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor has an eradication rate of only 74~76% and new therapeutic protocols may be necessary. The aim of this study was to investigate the effects of Lactobacillus as supplementation to anti-H. pylori regimens on H. pylori eradication rates and therapy-associated side effects. MATERIALS AND METHODS: The PubMed, Medline and Korean Medical Database were searched in January 2012, with no language restrictions, for randomized controlled trials; additional references were obtained from reviewed articles. We included trials comparing Lactobacillus supplementation to placebo or no treatment during anti-H. pylori regimens. Meta-analysis was performed with Review Manager. RESULTS: Eleven trials involving a total of 1,107 participants met the inclusion criteria. Compared with placebo or no intervention, Lactobacillus given along with anti-H. pylori regimens significantly increased the eradication rate [84.7% vs. 78.8%, odds ratio (OR) 1.75, 95% confidence interval (CI) 1.26~2.42] and reduced the risk of overall H. pylori therapy related adverse effects (35.4% vs. 48.6%, OR 0.56, 95% CI 0.38~0.81), particularly of diarrhea (7.5% vs. 20.6%, OR 0.31, 95% CI 0.18~0.54), bloating (19.2% vs. 29.9%, OR 0.53, 95% CI 0.32~0.88) and taste disturbance (17.6% vs. 34.8%, OR 0.37, 95% CI 0.21~0.64). There were no significant differences between groups in the risk of other adverse effects. CONCLUSIONS: Our review suggests that supplementation with Lactobacilli could be effective in increasing eradication rates of anti-H. pylori therapy. Furthermore, Lactobacilli showed a positive impact on some H. pylori therapy-related side effects, particularly diarrhea, bloating and taste disturbance.
